611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Widely Used Antipsychotics May Not Ease Delirium in ICUDisabling Hip Ailment Is Another Health Risk for Obese KidsE-Cigarettes Slowed Wound Healing in Animal Study3-Drug Therapy Might Be Cystic Fibrosis 'Breakthrough'Pounds Regained After Weight-Loss Op Can Tell Your Doc a LotCDC Warns of Polio-Like Virus Striking More U.S. KidsNew Nerve Stimulation Technique Might Relieve Back PainGluten-Free Craze a 'Double-Edged Sword' for Celiac PatientsHealth Tip: Know the Risks of Chicken PoxKids' Concussion Symptoms May Persist for a YearNew DNA-Based Test Approved to Help Verify Blood CompatibilityAHA: A Child's Eyes May Be a Window Into Later Heart Disease RiskGenes, Not Diet, May Be Key to Gout Flare-UpsDiabetes Drug Might Help Shield the Heart From Smog's Ill EffectsHealth Tip: Understanding MigrainesHospital Privacy Curtains May Be Home to Dangerous GermsWeight-Loss Surgery May Raise Gallstone Risk: StudyStudy Sees No Link Between Gout Drug, Kidney DiseaseHealth Tip: Prevent Mold Growth at HomeOne-Third of 'Gluten-Free' Restaurant Foods in U.S. Are Not: StudyHalf of Antibiotics Given Without Infection DiagnosisMediterranean Diet May Help Preserve Your Vision: StudyAHA: Researchers Suggest New Way to Possibly Eliminate Clogged ArteriesCan a 'Noah's Ark' of Microbes Save the World's Health?Brain Scans Suggest Pain of Fibromyalgia Isn't ImaginaryHealth Tip: Treat Your Child's AllergiesAHA: Doctors Could Do More to Help Smokers With Poor CirculationAcne's Stigma Can Take a Big Mental TollDoes Less-Invasive Surgery Make Sense for You?Type 2 Diabetes Tied to Raised Risk of Tumors, Cancer Deaths'Southern' Diet Blamed for Black Americans' Health WoesOne Football Rule Change Might Lower Concussion RiskDeep Space Travel May Damage GI Tract, Animal Study ShowsNew Drug Approved for Antibiotic-Resistant Lung DiseaseDrinking Enough Water Could Be Key to Avoiding UTIsThree New Genes Linked to Chronic Back Pain'Yo-Yo' Cardio Readings May Signal Heart RisksHealth Tip: Understanding Hip Replacement SurgeryCommon Heartburn Drugs Linked to Broken Hips in Dialysis PatientsWith 80,000 Flu Deaths Last Season, Experts Urge VaccinationHealth Tip: Manage Symptoms of AnemiaHealth Tip: Considering LASIK Surgery?Don't Turn a Blind Eye to Vision ProblemsExperimental Vaccine Shows Promise in Preventing TBAntibiotics May Cure Appendicitis -- No Operation NeededGun Victims More Likely to Die Than Other Trauma PatientsSpinal Implant Could Be Breakthrough for Paralyzed PatientsHealth Tip: Maintain Healthy Cholesterol5 Tips to Manage Your Child's AsthmaNew Compounds Might Help Stop Spread of Malaria
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

First Drug Approved for Rare Eye Disease

HealthDay News
by -- Scott Roberts
Updated: Aug 23rd 2018

THURSDAY, Aug. 23, 2018 (HealthDay News) -- Oxervate (cenegermin) has been approved by the U.S. Food and Drug Administration to treat neurotrophic keratitis, a rare disease of the eye's cornea.

The cornea is the clear layer that covers the colored portion at the front of the eye.

Neurotrophic keratitis affects fewer than five in 10,000 people, the FDA said. The disease, causing loss of corneal sensation, leads to damage of this vital part of the eye.

"While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating," Dr. Wiley Chambers, an ophthalmologist in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

Oxervate, produced as an eyedrop, was evaluated in a clinical study involving 151 people with neurotrophic keratitis. Some participants were given Oxervate, while others were given a placebo eye drop. Complete corneal healing was reported among 70 percent of people treated with Oxervate, compared with 28 percent of those given the placebo, the FDA said.

The most common side effects of the drug included eye pain, enlarged blood vessels in the eye, eye inflammation and watery eyes.

Oxervate is produced by the Italian firm Dompé farmaceutici.

More information

Visit the FDA to learn more.